KLF14: A Potential Drug Target and Biomarker (G136259)

Target Name: KLF14

NCBI ID: G136259

KLF14: A Potential Drug Target and Biomarker

Kruppel-like factor 14 (KLF14) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. KLF14 is a key regulator of gene expression and has been shown to play a role in a variety of cellular processes, including cell growth, differentiation, and inflammation.

The discovery of KLF14 as a potential drug target comes from a team of researchers at the University of California, San Diego, led by Dr. Zev Garton. The team found that KLF14 was highly expressed in various cancer types, including breast, ovarian, and prostate cancer. They also found that KLF14 was associated with cancer cell survival and invasiveness.

In addition to its potential as a drug target, KLF14 has also been identified as a potential biomarker for cancer. The team found that KLF14 was associated with the development and progression of various cancer types, including breast, ovarian, and prostate cancer. They also found that KLF14 was downregulated in cancer cells, which suggests that it may be a useful biomarker for cancer detection and treatment.

The team is now working on developing KLF14 as a potential drug and using it as a biomarker to predict the outcomes of cancer treatments. They are also exploring the potential uses of KLF14 in combination with other biomarkers to improve cancer diagnosis and treatment.

Overall, the discovery of KLF14 as a potential drug target and biomarker has significant implications for the development of new cancer treatments. With further research, it may be possible to identify new drug targets and biomarkers for cancer, and improve our ability to diagnose and treat this devastating disease.

Protein Name: KLF Transcription Factor 14

More Common Targets